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Background: A megaprosthesis may be used for reconstruction in patients with massive bone loss or a periprosthetic
fracture. Periprosthetic joint infection (PJI) may occur after a megaprosthesis reconstruction and may pose a major
challenge. The outcomes of managing PJI in patients with a megaprosthesis is relatively unclear. The aim of this study was
to investigate the clinical course and outcomes of PJI in patients with a megaprosthesis in place.
Methods: From a total of 219 patients who underwent megaprosthesis replacement for non-oncologic conditions, 38
(17.4%) developed subsequent PJI. A retrospective review of the medical record was performed to ascertain the course of
the PJI and treatment outcomes. Kaplan-Meier analysis was performed to evaluate the survival function, and the log-rank
test was used to assess differences in outcome measures.
Results: The surgical management of 33 patients with PJI included debridement, antibiotics, and implant retention
(DAIR) (82%), consisting of DAIR with modular component exchange (19 patients) and DAIR without component exchange
(8 patients); 2-stage exchange arthroplasty (9%); resection arthroplasty (6%); and a single-stage revision arthroplasty
(3%). The Kaplan-Meier survivorship analysis demonstrated that the overall survival rate was 65.1% at 2 years. The
mortality rate was 15%, with many patients undergoing salvage procedures including amputation (18%), arthrodesis (6%),
and resection arthroplasty (6%).
Conclusions: The rate of PJI after megaprosthesis reconstruction, 17% in this study, appears to be very high. The
management of PJI in these patients is challenging, with 1 of 3 patients undergoing failed treatment. Despite the limited
options available, DAIR seems to be an appropriate treatment strategy for some of these patients. Further data on a larger
cohort are needed to assess the success of various surgical procedures and predictors of failure in this challenging
patient population.
Level of Evidence: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.

M

assive bone loss or periprosthetic fracture is often
encountered in revision arthroplasty that may
necessitate the use of a megaprosthesis. However, the
use of a megaprosthesis is not without complications. One of
the most devastating complications following a megaprosthesis
implantation is periprosthetic joint infection (PJI), which
occurs at a signiﬁcantly higher rate than following other primary or revision procedures1,2. This increased propensity for
infection often occurs because of the associated longer operative
time and larger soft-tissue dissection and because the patient
who undergoes multiple revisions and has massive bone loss is
more likely to be a poor host.
PJI is a serious complication after total joint arthroplasty
and is associated with remarkable morbidity and mortality.

However, PJI following a megaprosthesis introduces several
new challenges given the morbidity associated with revision
or explantation of a megaprosthesis. Given the relative rarity
of the use of a megaprosthesis, little is known with regard to
the fate of a patient with a PJI occurring after a megaprosthesis is implanted. Outcomes after arthroplasty using nonmegaprostheses are far from optimal, with high rates of
reinfection, mortality, and need for subsequent salvage procedures. Thus, it is expected that outcomes following PJI
involving a megaprosthesis may be even worse. Due to the
lack of literature on an infection involving megaprostheses, it
is difﬁcult for surgeons to recommend the most appropriate
treatment option and manage patient expectations without
knowing the associated complication proﬁle.
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This study was designed to investigate the success of treating
patients with PJI after megaprosthesis placement and to determine the survival rate of megaprostheses with and without PJI.
Materials and Methods
fter institutional board review approval, a retrospective
review of medical records and our institutional database
was performed between 2000 and 2018. A total of 219
megaprostheses were implanted in this time period for
non-oncologic etiologies, including 73 proximal femoral
replacements (PFRs) and 146 distal femoral replacements
(DFRs) (Fig. 1). The protocol for antibiotic prophylaxis, anticoagulation, and rehabilitation was similar or the same for all
patients. Weight-based (15 mg/kg), ﬁrst-generation cephazolin
was administered for 24 hours. All distal femoral replacements
were cemented, and some of the proximal femoral replacements
were cemented. When used, cement was antibiotic-impregnated.
All patients with a megaprosthesis who subsequently developed
PJI and had a minimum follow-up of 1 year were included in this
study. A total of 38 megaprosthesis cases (17.4%) developed
subsequent PJI after megaprosthesis placement according to
recent International Consensus Meeting (ICM) criteria3. The
initial indication of those megaprosthesis replacements was prior
PJI (20 [32%] of 63 cases), periprosthetic fracture (10 [12%] of 81
cases), and aseptic loosening (8 [12%] of 67 cases). Five additional
patients who developed PJI were excluded because they did not
have a minimum of 1-year follow-up, but no complication, reoperation, or death occurred in this group of 5 patients. The ﬁnal
analyses were on 33 infected megaprostheses, including 15 PFRs
(46%) and 18 DFRs (55%) (Fig. 1, Table I).

A

Surgical Technique
The surgical treatment selected was largely based on the surgeon’s preference and acuity of infection. Moreover, the ﬁxation status of the components, patient comorbidity, and
intraoperative ﬁndings inﬂuenced the choice of surgical option.
For patients who underwent debridement, antibiotics, and
implant retention (DAIR), debridement of all devitalized
osseous and soft tissues was performed in all cases. At least 6 L
of various irrigation solutions were used depending on the
surgeon’s preference. The decision to perform a modular
component exchange was also made by the treating surgeon. It
is customary that all modular parts of a megaprosthesis are
exchanged during a DAIR procedure unless the prosthesis is
custom-made or modular parts are not available off the shelf.
In the latter circumstance, the modular part is usually scrubbed
physically by a brush and/or immersed in an antiseptic solution. During DAIR, surgeons also utilized many liters of antiseptic solution for irrigation that includes dilute povidone
iodine (0.5%) and dilute hypochlorite solution (0.125%). A
total of 3 to 5 tissue samples were collected for culture and were
sent for routine aerobic and anaerobic bacterial, fungal, and
acid-fast cultures. For patients with a 2-stage exchange, components were explanted and a static spacer was placed after
debridement of bone and soft tissues. The spacers included
dual antibiotics containing both 3 g of vancomycin and 3.6 g of

Fig. 1

Flowchart of patient inclusion.

tobramycin per 40-g package of bone cement if there is no
contraindication. The decision to undergo reimplantation was
based on numerous metrics that included suitability of the
patient, serum markers, and other parameters. Following the
surgical procedure, parenteral antibiotic therapy was introduced for 6 weeks and was followed by oral antibiotics for
6 months to 1 year, which was initiated on the basis of consultation with an infectious disease specialist and followed the
treatment response, clinical follow-up, laboratory markers, and
radiography per the institute protocol.
Outcome Variables
A manual review of medical records was conducted to collect
pertinent information including medical comorbidities, operative information, organism information, subsequent surgical
procedures, and mortality. The primary outcome was treatment
failure, which was deﬁned as unplanned revision or salvage
surgical procedures or implant removal. All antibiotic treatment
was given in consultation with an infectious disease specialist
who determined the dose and duration of the antimicrobials.
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TABLE I Demographic Data, Etiology, and Prosthesis Type According to Type of PJI
Acute Postoperative
PJI Group (N = 12)

Acute Hematogenous
PJI Group (N = 10)

Chronic PJI Group
(N = 11)

P Value

68.3 ± 14.2

65.1 ± 12.4

64 ± 11.2

0.694

Age* (yr)
Female sex†
Body mass index* (kg/m2)
Charlson Comorbidity Index*
Diabetes†
Rheumatoid arthritis†
Smoking†

8 (67%)

6 (60%)

6 (55%)

0.837

32.8 ± 5.9

32.5 ± 7.6

34 ± 9

0.88

1 ± 1.7

1.1 ± 1.8

1.1 ± 1.3

0.986

0

1 (10%)

0

0.305

0

0

0

5 (42%)

2 (20%)

5 (45%)

0.357

No. of previous operations*

4.3 ± 1.9

3.5 ± 2.6

5±3

0.415

Estimated blood loss* (mL)

775 ± 711.5

518.8 ± 334.8

1,400 ± 1,444.8

0.165

Operative time* (min)

195.3 ± 88.1

179.6 ± 37.8

217.3 ± 74.5

0.582

Follow-up duration* (mo)

24.6 ± 17.6

49 ± 31.7

36.6 ± 26.5

0.1

7 (58%)

4 (40%)

9 (82%)

Etiology for megaprosthesis†

0.404

Prior PJI
Fracture

3 (25%)

3 (30%)

2 (18%)

Aseptic loosening

2 (17%)

3 (30%)

0 (0%)

6 (50%)
6 (50%)

1 (10%)
9 (90%)

8 (73%)
3 (27%)

Type of prosthesis†

0.014

PFR
DFR

*The values are given as the mean and standard deviation. †The values are given as the number of patients, with the percentage in parentheses.

Statistical Analysis
This study used descriptive statistics for evaluation of categorical and continuous data. Categorical variables were analyzed using the chi-square test or the Fisher exact test, and
continuous variables were analyzed using the independent t test
or the Mann-Whitney U test. An alpha level of 0.05 was used to
determine signiﬁcance. Kaplan-Meier survivorship curves were

generated using a revision surgical procedure or treatment
failure as an end point. Differences in survivorship were evaluated based on the log-rank test. All analyses were performed
using SPSS Statistics for Macintosh, version 26.0 (IBM).
Source of Funding
None.

TABLE II Operative Treatment of Subsequent PJI According to Type of PJI and Initial Etiology of the Megaprosthesis Reconstruction*
Type of PJI

Prosthesis Etiology

No. of Patients Acute Postoperative Acute Hematogenous Chronic
Total no. treated

PJI

Fracture Aseptic Loosening

33 (11)

12 (2)

10 (5)

11 (4)

20 (8)

8 (2)

5 (1)

Operation
DAIR

27 (10)

11 (2)

9 (5)

7 (3)

16 (7)

7 (2)

4 (1)

With modular component
exchange

19 (6)

7 (1)

8 (4)

4 (1)

11 (4)

5 (2)

3 (0)

Without modular component
exchange

8 (4)

4 (1)

1 (1)

3 (2)

5 (3)

2 (0)

1 (1)

2-stage exchange

3 (1)

0

1 (0)

2 (1)

2 (1)

1 (0)

0

1-stage exchange

1 (0)

0

0

1 (0)

1 (0)

0

0

Resection arthroplasty

2 (0)

1 (0)

0

1 (0)

1 (0)

0

1 (0)

*The values are given as the total number of patients, with the number of patients who underwent failed treatment in parentheses.
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Fig. 2

Kaplan-Meier plot comparing survival functions in different types of PJI. Cum = cumulative, acPOPJI = acute postoperative PJI, acHemPJI = acute
hematogenous PJI, and chPJI = chronic PJI.

Results
he mean follow-up duration (and standard deviation) for
all patients was 36 ± 26.2 months. Of the 33 infected

T

megaprostheses that were included in the ﬁnal data, DAIR was
the most commonly performed surgical procedure (82% [27
patients]). This consisted of 11 cases in the acute postoperative

Fig. 3

Kaplan-Meier plot comparing survival functions between DAIR with and without modular-component exchange. Cum = cumulative.
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TABLE III Descriptive Data for Patients Who Underwent Failed Treatment*

Patient
No.

Etiology of
Prosthesis Megaprostheses

Former Culture
Results

Important
Clinical Notes

Type of PJI

First
Operation
for PJI
Treatment

Organism(s)

Second
Operation
for
Treatment

Time from
First
Operation
to Final
Operation
(mo)

Final
Operation

1

PFR

Prior PJI

MRSA

Sinus tract

Chronic

DAIR

Mixed

Resection

5

2

PFR

Prior PJI

Negative

Sinus tract

Chronic

DAIR
modular
component
exchange

Serratia
marcescen

2-stage
exchange
revision,
then
amputation

0.7

Hip
disarticulation

3

PFR

Prior PJI

NA

—

Chronic

2-stage
exchange
revision

Proteus
mirabilis

Resection

7.1

Girdlestone

4

DFR

Prior PJI

MSSA

Tooth
extraction

Acute
DAIR
hematogenous modular
component
exchange

Amputation
Coagulasenegative
Staphylococcus

9.5

Above-theknee
amputation

5

DFR

Fracture

—

MSSA
bacteremia

Acute
DAIR
hematogenous modular
component
exchange

MSSA

0.23

Above-theknee
amputation

6

DFR

Prior PJI

MSSA

Previous pain
1 week

Acute
DAIR
hematogenous modular
component
exchange

2-stage
Coagulaseexchange
negative
Staphylococcus revision

7

DFR

Prior PJI

MSSA

Postoperative
day 21

Acute
postoperative

Enterococcus
faecalis

8

DFR

Fracture

—

Heel ulcer

Acute
DAIR
hematogenous modular
component
exchange

9

DFR

Aseptic
loosening

—

Cardiac
procedure

10

DFR

Prior PJI

Postoperative
Coagulaseday 80
negative
Staphylococcus

11

DFR

Prior PJI

Mixed

—

Resection,
then
amputation

Girdlestone

0.6

DFR and
lifelong
antibiotic

Resection,
then
arthrodesis

2.3

Intramedullary
knee
arthrodesis

Group B
Streptococcus

Amputation

6.1

Above-theknee
amputation

Acute
DAIR
hematogenous

NA

Resection,
then fusion

6

Acute
postoperative

DAIR

Culturenegative

Amputation

2.9

Above-theknee
amputation

Chronic

DAIR

Mixed

Amputation

3.9

Above-theknee
amputation

DAIR
modular
component
exchange

Intramedullary
knee
arthrodesis

*MRSA = methicillin-resistant Staphylococcus aureus, MSSA = methicillin-sensitivity Staphylococcus aureus, and NA = not available.

group, 9 cases in the acute hematogenous group, and 7 cases
in the chronic PJI group. Other surgical treatments included
2-stage exchange arthroplasty (9% [3 patients]), resection
arthroplasty (6% [2 patients), and a single-stage exchange (3%
[1 patient]) (Table II). Treatment failure occurred in 11
patients (33%). The mean time to revision after the ﬁrst PJI
treatment was 1.3 ± 0.9 months for acute postoperative PJI,
36.7 ± 40.5 months for acute hematogenous PJI, and 17.9 ±
34.7 months for chronic PJI. The infection rate based on the
indication for a megaprosthesis was 40% for the prior PJI
group, 25% for the fracture group, and 20% for the aseptic
loosening group (p = 0.592).

DAIR treatment demonstrated an overall success rate of
63% (Table II). Treatment success was higher when modular
components were exchanged (68% for DAIR with a modular
component exchange compared with 50% for DAIR without a
modular component exchange). However, this difference did
not reach signiﬁcance with the given number of patients in the
cohort. A single DAIR treatment was successful in 30% of cases,
and a second DAIR operation was performed in 53% of
patients and achieved treatment success in 44% of these
patients. If ‡3 DAIRs were performed, the treatment success
was only 25%. Treatment success with DAIR was the highest in
patients with acute postoperative PJI (82% [9 of 11]). However,
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permanent resection arthroplasty of the hip (Fig. 4, Table III).
Reinfection treatment failure was found in 40% (8 of 20) in the
prior PJI group: acute postoperative PJI for 2 cases, acute
hematogenous PJI for 2 cases, and chronic PJI for 4 cases. Four
of 8 patients from this group later underwent lower-limb
amputation (Table III).
The overall mortality rate was 15% (5 patients), with a
mean time to mortality of 15.4 ± 13 months. The microorganism isolation is demonstrated in Table IV, in which the most
common organisms were mixed organisms at 27% and
coagulase-negative Staphylococcus at 18%.
Discussion
he management of PJI after megaprosthesis reconstruction
is extremely challenging, especially given the paucity of
literature with regard to outcomes of a PJI after megaprosthesis placement. To our knowledge, this is the ﬁrst reported

T

TABLE IV Organisms Isolated in Cases of PJI After
Megaprosthesis Implantation*
Organism(s)
Coagulase-negative Staphylococcus
Fig. 4

Patients†
6 (18%)

Staphylococcus aureus

Anteroposterior radiograph of a right knee that underwent intramedullary

MSSA

2 (6%)

knee arthrodesis at 2 years after megaprosthesis placement. This

MRSA

1 (3%)

patient had had subsequent PJI after the megaprosthesis placement and
treatment failure following DAIR; resection arthroplasty was performed,

Streptococcus species

4 (12%)

Serratia marcescens

2 (6%)

but the patient was a poor candidate for distal femoral replacement

Proteus mirabilis

2 (6%)

Culture-negative

4 (12%)

Mixed organisms

9 (27%)

reimplantation.

treatment success was only 44% in patients with acute hematogenous PJI (p = 0.212). When DAIR was performed for
patients with chronic PJI, the success rate was 57%.
The overall survivorship, being deﬁned as free of failure,
was 65% at 2 years. All failures occurred within the ﬁrst year
after the surgical intervention. Survivorship was higher, but not
signiﬁcantly (p = 0.211), for patients with acute postoperative
PJI (83%) than patients with acute hematogenous PJI (42%) or
chronic PJI (63.6%) (Fig. 2).
When stratiﬁed by PJI treatment, survivorship at 2 years
was 61% for patients who underwent DAIR and 67% for
patients who underwent 2-stage exchange arthroplasty (p =
0.739). Patients who underwent DAIR with a modular component exchange had a higher survival rate at 2 years (66%)
than patients who underwent DAIR without a modular component exchange (50%) (p = 0.511) (Fig. 3).
Uncontrolled infection occurred in 11 patients, requiring
several salvage and subsequent surgical procedures (Table III).
One patient was given lifelong antibiotic suppression treatment, and 6 patients required amputation that included 1 hip
disarticulation and 5 above-the-knee amputations. Two
patients needed knee arthrodesis and 2 patients underwent

Actinomyces species, Bacteroides
fragilis, Gemella species
Corynebacterium species,
Staphylococcus epidermidis
Cutibacterium acnes, coagulasenegative Staphylococcus
Coagulase-negative Staphylococcus,
Klebsiella pneumoniae, Pseudomonas
aeruginosa
S. epidermidis, Candida lusitaniae
MSSA, Streptococcus species
Enterococcus faecalis, K. pneumoniae,
S. epidermidis
Corynebacterium species, Candida
species
C. acnes, coagulase-negative staphylococcus, E. faecalis
Other

3 (9%)

*MSSA = methicillin-sensitive Staphylococcus aureus, and MRSA =
methicillin-resistant Staphylococcus aureus. †The values are given
as the number of patients, with the percentage in parentheses.
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study to reveal the surgical options for and outcomes of a PJI
after megaprosthesis placement after a non-oncologic megaprosthesis reconstruction. This study demonstrates that the
overall PJI rate after megaprosthesis reconstruction is high
(up to 17.4%) even in the ﬁrst megaprosthesis replacement,
especially in the prior PJI group, in which one-third of
patients developed reinfection after megaprosthesis replacement. We found that DAIR was a viable treatment option for
acute postoperative PJI in patients with a megaprosthesis in
place, with a success rate of 82%, and the overall success rate
for treatment of PJI of any type was 63%, which compared
favorably with the 67% overall success rate of 2-stage
exchange, without the increased potential for surgical morbidity associated with complete implant removal. However,
DAIR performed substantially worse for acute hematogenous
PJI, with a failure rate of 56%, and chronic PJI, with a failure
rate of 43%. Furthermore, if DAIR is to be performed,
modular component exchange might improve the success
rate, which was slightly higher but not signiﬁcantly so in the
current study. A high rate of salvage procedures and mortality
was also observed in our study.
Although this is the ﬁrst study on PJI after megaprosthesis
placement, to our knowledge, there is some literature on the use
of a megaprosthesis for a prior infection. Alvand et al.4 reviewed
69 patients with megaprostheses for PJI management and
reported an infection rate of 28%. Furthermore, Corona et al.5
analyzed infection rates following the use of a megaprosthesis at
reimplantation in patients with chronic PJI who demonstrated
bone loss and reported an infection rate of 17%. The 2 aforementioned studies found that the 2 most commonly isolated
pathogens were coagulase-negative staphylococcal and polymicrobial infections, which is also consistent with our ﬁndings
(Table IV). When a megaprosthesis is used for fracture, a systematic review found that the infection rate was 29%6. However,
the treatment outcomes after reinfection were not reported.
Ercolano et al.1 studied infection after megaprosthesis implantation for both oncologic and non-oncologic conditions in a
series of 31 patients who developed infection after the megaprosthesis placement and found that the treatment failure rate
was 52%. This higher failure rate may be attributed to the fact
that 40% of treatment failure occurred in oncologic patients,
who may have been poor hosts. The authors utilized DAIR, 1 and
2-stage revision, and amputation and found that no individual
surgical method was preferred.
When evaluating the outcome of DAIR speciﬁcally, the
current study found that it is a viable option with a relatively
high success rate for patients who experience an acute PJI after
the megaprosthesis is in place. A repeat DAIR in these patients
appeared to improve the outcome only marginally. Our data
add weight to the recent ICM recommendations that DAIR

7

should be employed in patients with acute PJI after a megaprosthesis placement2. If DAIR is to be performed, our study
advocates that modular component exchange should be performed, which is consistent with the recommendations of the
ICM2. The indications for DAIR were likely expanded in the
presence of a megaprosthesis given the morbidity of removing
all components, massive bone loss and soft-tissue voids, and
concern for instability. This also explains why DAIR was utilized in 64% of cases of chronic PJI, despite the propensity for
increased failure rates.
There were several limitations to this study that should be
considered. First, this study was a retrospective review and
information was thus limited to the medical record. It was
therefore difﬁcult to determine the surgeon’s individual rationale
for choosing a particular surgical plan, which introduced the
possibility of a selection bias. Second, because DAIR was the
predominant surgical procedure chosen, we had only a few
patients with 2-stage and 1-stage exchanges, which made it
difﬁcult for us to compare the different treatment options.
Third, given the relatively low sample size, a multivariate analysis
could not be performed, which made it difﬁcult to control for
potential confounding variables. Finally, we were unable to
obtain information on postoperative functional outcomes.
In summary, patients with a megaprosthesis for nononcologic conditions demonstrated a high rate of PJI and
demonstrated high rates of subsequent reinfection after PJI
treatment. DAIR was the most often performed procedure for
infection following megaprosthesis placement, and success was
most often achieved in patients with acute postoperative PJI
and when modular exchange was performed. When failure of
DAIR occurs, there may be a role for repeat DAIR. Surgeons
should consider these factors when deciding on a surgical plan
and counseling patients on expected outcomes. n
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